Last reviewed · How we verify
Hepatitis A vaccine
Hepatitis A vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection.
Hepatitis A vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection. Used for Prevention of hepatitis A infection in adults and children.
At a glance
| Generic name | Hepatitis A vaccine |
|---|---|
| Also known as | Vaqta, Avaxim, Havrix, HAVRIX, VAQTA™ or Havrix™ |
| Sponsor | MacroGenics |
| Drug class | inactivated viral vaccine |
| Target | Hepatitis A virus surface antigens |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated hepatitis A virus that triggers both humoral (antibody) and cellular immune responses. This priming of the adaptive immune system enables rapid recognition and neutralization of wild-type hepatitis A virus upon exposure, preventing viral replication and disease development.
Approved indications
- Prevention of hepatitis A infection in adults and children
Common side effects
- Injection site soreness or erythema
- Headache
- Fatigue
- Myalgia
- Low-grade fever
Key clinical trials
- DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (PHASE1)
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- R21/Matrix-M in African Children Against Clinical Malaria (PHASE3)
- Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection (PHASE1, PHASE2)
- The COMBAT HBV Feasibility Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hepatitis A vaccine CI brief — competitive landscape report
- Hepatitis A vaccine updates RSS · CI watch RSS
- MacroGenics portfolio CI